Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction

Aim . To evaluate the cost-effectiveness of achieving target indicator "Reduction cardiovascular mortality population" State Program "Health Development" when using drugs valsartan+sacubitril, dapagliflozin and empagliflozin in patients with New York Heart Association (NYHA) class II-IV heart failure reduced ejection fraction ≤40% s 2023-2024. Material methods The population was Russian who received preferential medicines last two years after an acute disease. size determined on basis literary statistical sources. predict death, a parametric modeling method used based published data from clinical trials. amount drug costs required to prevent one as well achieve for reducing mortality, calculated each comparator whole country separately region. Results cost 1 st year therapy death case valsartan+sacubitril RUB 3,99 million, — 2,63 4,43 million. There were following empagliflozin: 2023 2197,9 1451,5 million 2435,9 respectively; 2024 627,4 407,7 706,9 respectively. Conclusion Among agents considered, seems be most effective preventing mortality"